NeOnc signs $50M non-binding term sheet with Quazar for UAE clinical platform expansion

NEONC TECHNOLOGIES HOLDINGS, INC.

$50M equity investment at $25/share from Quazar Investment; board approved June 30, 2025.
Formation of NuroMENA Holdings and NuroCure in UAE to run clinical trials for NEO100 and NEO212.
70% of funds to buy NTHI common stock at $25/share; 30% for clinical trials and infrastructure.
Conditions include sub-license from USC Stevens Center, offering docs, and two-year plan within 120 days.
Partnership leverages Cleveland Clinic Abu Dhabi for trials under US FDA protocols.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.